EBMT Educational Meeting from the Severe Aplastic Anemia and Infectious Diseases Working Parties.

EBMT Educational Meeting from the Severe Aplastic Anemia and Infectious Diseases Working Parties. Curr Drug Targets. 2016 Jun 22; Authors: Tichelli A, Rovó A Abstract Prognosis of patients with acquired aplastic anemia (AA) treated with hematopoietic stem cell transplantation (HSCT) has greatly improved. Nevertheless, long-term morbidity may occur and are responsible for the persistent increased death rates as compared to general population. Most late effects evolve during the first 10 years post-transplant; however, some of them may appear later. Patients with AA undergoing a HSCT from a matched sibling donor (MSD) present a lower incidence of non-malignant late complications when compared to patients transplanted for a malignant disease. In case of unrelated HSCT, the burden of morbidity increases significantly, mainly because often more intensive conditioning including irradiation is used and because many of these patients are pretreated with immunosuppression. Furthermore, with the introduction of new transplantation strategies older patients with AA become candidates for HSCT yielding likely an increase in the morbidity rate. The main risk factor for late effects is radiotherapy, and in non-irradiated patients, chronic GVHD, its treatment, as well as previous immunosuppressive therapy. The main non-malignant late complications in AA are avascular necrosis of the bone, gonadal dysfunction with infertility and cataracts. Secondar...
Source: Current Drug Targets - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Targets Source Type: research